Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CEL-SCI Co. stock logo
CVM
CEL-SCI
$0.25
+5.4%
$0.26
$0.18
$2.22
$21.44M0.51.05 million shs637,065 shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.04
-1.0%
$1.01
$0.81
$1.76
$22.26M0.76128,685 shs35,353 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.17
+10.8%
$3.22
$2.57
$7.26
$19.65M0.598,970 shs26,055 shs
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
$1.68
-1.2%
$1.51
$1.30
$18.39
$6.05M-0.21846,708 shs30,329 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CEL-SCI Co. stock logo
CVM
CEL-SCI
+5.38%-4.21%+33.19%-32.75%-81.54%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-0.95%-0.95%+14.29%-5.45%-33.76%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+10.84%+5.67%+6.02%-24.25%-51.31%
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
-1.17%+10.89%+23.53%-10.16%+1,112.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
2.6391 of 5 stars
3.75.00.00.00.00.81.3
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.946 of 5 stars
0.03.00.00.02.71.70.6
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00
N/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.33
Buy$10.00861.54% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NLSP, CVM, ENLV, and NAII Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/3/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
3/24/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$6.00 ➝ $7.00
3/3/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/A$0.15 per shareN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$1.62 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$121.85M0.16N/AN/A$12.77 per share0.25
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CEL-SCI Co. stock logo
CVM
CEL-SCI
-$26.92M-$0.48N/AN/AN/AN/A-238.05%-104.65%N/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$29.07M-$0.73N/AN/AN/AN/A-67.57%-58.45%6/13/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.29N/AN/A-6.26%-9.36%-4.82%5/13/2025 (Estimated)
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
-$12.17MN/A0.00N/AN/AN/AN/A5/21/2025 (Estimated)

Latest NLSP, CVM, ENLV, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/31/2025Q4 2024
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.23-$0.07-$0.23N/AN/A
2/14/2025Q2 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$34.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.66
1.07
1.09
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
9.71
9.71
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.70
1.50
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/A
0.15
N/A

Institutional Ownership

CompanyInstitutional Ownership
CEL-SCI Co. stock logo
CVM
CEL-SCI
12.08%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
1.02%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/A

Insider Ownership

CompanyInsider Ownership
CEL-SCI Co. stock logo
CVM
CEL-SCI
16.24%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
12.28%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
16.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
CEL-SCI Co. stock logo
CVM
CEL-SCI
4384.12 million64.67 millionOptionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7021.41 million18.78 millionOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.20 million4.90 millionNot Optionable
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
63.60 million3.01 millionNot Optionable

Recent News About These Companies

NLS Pharmaceutics, Kadimastem announce up to $3M equity financing
NLS Pharmaceutics announces new preclinical data for AEX-2
NLS Pharmaceutics files $75M mixed securities shelf
NLS Pharmaceutics files to sell 645,161 common shares for holders
NLS Pharmaceutics’ merger approved by Kadimastem shareholders
NLS Gains on Deal with Kardimastem

New MarketBeat Followers Over Time

Media Sentiment Over Time

CEL-SCI stock logo

CEL-SCI NYSE:CVM

$0.25 +0.01 (+5.38%)
Closing price 05/8/2025 04:00 PM Eastern
Extended Trading
$0.25 0.00 (-0.71%)
As of 05/8/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.04 -0.01 (-0.95%)
Closing price 05/8/2025 03:52 PM Eastern
Extended Trading
$1.04 0.00 (0.00%)
As of 05/8/2025 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.17 +0.31 (+10.84%)
Closing price 05/8/2025 04:00 PM Eastern
Extended Trading
$3.17 0.00 (0.00%)
As of 05/8/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

NLS Pharmaceutics stock logo

NLS Pharmaceutics NASDAQ:NLSP

$1.68 -0.02 (-1.17%)
Closing price 05/8/2025 03:52 PM Eastern
Extended Trading
$1.65 -0.03 (-1.79%)
As of 05/8/2025 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.